(2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: (2S)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2S)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
• 化学式: C₂₅H₂₈O₆
• 分子量: 424.5
• InChiKey: XRYVAQQLDYTHCL-WNSKOXEYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：KINKI UNIVERSITY

  公开号：US20160096815A1

  公开（公告）日：2016-04-07

  The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R 1 and R 2 independently represents H, —OH or —OR 11 , wherein R 11 represents a C 1-3 alkyl group; each of R 3 and R 4 independently represents H, —OH or —OR 12 , wherein R 12 represents a C 1-3 alkyl group; and each of R 5 and R 6 independently represents H, a halogen atom, a C 1-10 alkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a phenyl group (which may be substituted by a C 1-6 alkoxy group or a halogen atom), a —C 1-3 alkyl-phenyl group (which may be substituted by a C 1-6 alkyloxy group or a halogen atom) or a C 10-50 prenyl group.)

  本发明提供了一种T型钙通道抑制剂，该化合物由式（1）表示，其药学上可接受的盐或该化合物的溶剂。本发明还提供：该T型钙通道抑制剂；含有该T型钙通道抑制剂的药物产品；以及治疗或预防疾病的治疗剂或预防剂，其有效作用是T型钙通道抑制作用。（在式（1）中，每个R1和R2独立地表示H，—OH或—OR11，其中R11表示C1-3烷基；每个R3和R4独立地表示H，—OH或—OR12，其中R12表示C1-3烷基；每个R5和R6独立地表示H，卤素原子，C1-10烷基，C2-6烯基，C2-6炔基，苯基（可能被C1-6烷氧基或卤素原子取代），—C1-3烷基苯基（可能被C1-6烷氧基或卤素原子取代）或C10-50戊二烯基。）
• T-type calcium channel inhibitor
  申请人：KINKI UNIVERSITY

  公开号：US10633358B2

  公开（公告）日：2020-04-28

  The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R1 and R2 independently represents H, —OH or —OR11 wherein R11 represents a C1-3 alkyl group; each of R3 and R4 independently represents H, —OH or —OR12, wherein R12 represents a C1-3 alkyl group; and each of R5 and R6 independently represents H, a halogen atom, a C1-10 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a phenyl group (which may be substituted by a C1-6 alkoxy group or a halogen atom), a —C1-3 alkyl-phenyl group (which may be substituted by a C1-6 alkyloxy group or a halogen atom) or a C10-50 prenyl group.)

  本发明提供了一种 T 型钙通道抑制剂，它是由式（1）代表的化合物、该化合物的药学上可接受的盐或该化合物的溶液。本发明还提供：这种 T 型钙通道抑制剂；含有这种 T 型钙通道抑制剂的药品；以及一种治疗剂或疾病预防剂，其有效作用为 T 型钙通道抑制作用。式（1）中，R1 和 R2 各自独立地代表 H、-OH 或-OR11，其中 R11 代表 C1-3 烷基；R3 和 R4 各自独立地代表 H、-OH 或-OR12，其中 R12 代表 C1-3 烷基；R5和R6各自独立地代表H、卤素原子、C1-10烷基、C2-6烯基、C2-6炔基、苯基（可被C1-6烷氧基或卤素原子取代）、-C1-3烷基苯基（可被C1-6烷氧基或卤素原子取代）或C10-50链烯基。)
• EP3000465B1
  申请人：——

  公开号：EP3000465B1

  公开（公告）日：2021-03-31
• TOPICAL BASE AND ACTIVE AGENT-CONTAINING COMPOSITIONS, AND METHODS FOR IMPROVING AND TREATING SKIN
  申请人：Schlessinger Joel

  公开号：US20130177618A1

  公开（公告）日：2013-07-11

  The invention provides skin-protecting and penetrating, easy-to-administer base and active agent-containing compositions, such as those including hydrocortisone, for treating the skin of mammals for different dermatologic disorders. This is effected by topically administering effective amounts of the compositions thereto in forms that address the skin and mucosa of the mouth and lips, and the rest of the body. Additionally, an optional flavoring addition to these products affords significantly better tasting, and less bitter, compositions, allowing a more pleasant experience and better compliance by patients. The compositions include a unique formulation of FANCOL VB, Natunola Castor 1023, Finsolv TN, bees wax and, optionally, one or a plurality of plant or plant seed oils, fatty alcohols, fats and flavorings, in desirable weight percents thereof, in various forms, and preferably in a form of a solid roll-on stick in a variety of sizes and of a jar or pot.
• US8968755B2
  申请人：——

  公开号：US8968755B2

  公开（公告）日：2015-03-03